Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU

Funding: The preparation of this review was not supported by any external funding.

Conflicts of interest: K. McKeage and K.A. Lyseng-Williamson are employees of Adis-Springer, are responsible for the article content and declare no conflicts of interest.

Further information about this Adis Drug Q&A can be found here.

Abstract

Triptorelin [available in 1-, 3- and 6-month intramuscular sustained-release (SR) formulations] is a gonadotropin-releasing hormone (GnRH) agonist that effectively achieves and maintains castrate serum testosterone levels and is generally well tolerated in men with locally advanced or metastatic prostate cancer. The availability of the triptorelin 3- and 6-month SR formulations allows flexibility of treatment schedules for the patient and physician. The triptorelin 6-month SR formulation may improve convenience and patient’s potential adherence, health-related quality of life and resource use relative to GnRH agonists that require more frequent administration. This review provides a summary of the clinical evidence regarding the use of the 3- and 6-month SR formulations of triptorelin in the treatment of locally advanced and metastatic prostate cancer in the EU.

Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2017